Developer docs
API playgroundTry for free, no card

Search company profiles

Engitix

Full company profile

uuid00023a3

Namestring
Engitix
Legal namestring
ENGITIX LIMITED
Websiteurl
engitix.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Engitix is a London-based biotechnology company founded in 2016 as a spin-out of University College London's Institute for Liver and Digestive Health, developing a proprietary human extracellular matrix (ECM) drug discovery platform for fibrosis, inflammation, and solid tumours. The platform combines tissue- and disease-specific human ECM scaffolds, a 3D phenotypic screening capability, and the Engitomix bioinformatics platform — built on one of the world's largest proprietary human ECM datasets integrating mass-spectrometry, RNA-sequencing, imaging, and clinical metadata with AI/ML-driven analytics. Engitix holds an exclusive license from UCLB to foundational ECM decellularization patents invented by co-founder Dr Giuseppe Mazza.

The company operates a B2B partnership model, monetizing its platform through multi-year, multi-programme collaborations with pharmaceutical and biotechnology companies. Partnerships with Takeda (up to $500M for advanced fibrotic liver diseases plus up to $300M for fibrostenotic IBD), GSK (£44.5M upfront plus up to £118M per target in milestones for liver fibrosis regression), Dompè farmaceutici (Exscalate AI integration plus equity), and Morphic Therapeutic (fibrostenotic IBD) generate upfront fees, near-term payments tied to target validation, preclinical/development/regulatory/commercial milestones, and royalties on commercialized products. Engitix retains full control over its assets in these collaborations.

In parallel, Engitix has built an internal proprietary pipeline of discovery-stage assets — EGTX003 (inflammation/fibrosis), EGTX004 (solid tumours and advanced fibrosis), and EGTX006 (advanced fibrosis) — financed through approximately $79M of disclosed venture funding, led by Netherton Investments (Mike Platt/BlueCrest Capital) with Dompè as co-lead of the 2022 Series A. Headcount has grown to approximately 60-80 staff across London headquarters (WestWorks, White City Place) and a Cambridge, MA US subsidiary, supported by ISO 27001 certification and an expanding leadership team drawn from J&J, Novartis, Roche, GSK, and other major pharma organizations.

Short descriptiontext

Engitix is a London-based biotechnology company that partners with pharmaceutical companies to discover and validate ECM-targeted therapeutics for fibrosis, inflammation, and solid tumours using its proprietary human extracellular matrix drug discovery platform and bioinformatics data assets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, extracellular matrix platform, fibrosis therapeutics, oncology drug discovery, biopharmaceutical research
Industry4 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Biopharmaceutical Drug Discovery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership and Licensing Revenue
TypeLicensing Royalties
Description

Engitix generates revenue through strategic partnerships with pharmaceutical companies. Partners pay upfront fees, near-term payments for target validation, and milestone payments tied to preclinical, development, regulatory, and commercial achievements. Royalties are received on sales of commercialized products.

engitix.com
2Platform Technology Access Fees
TypeProfessional Services
Description

Partners receive access to ECM platform capabilities, facilities, and expertise in exchange for fees and milestone considerations. Dompé partnership included direct access to facilities, resources, and Exscalate AI drug discovery platform.

engitix.com
3Research Collaboration Payments
TypeProfessional Services
Description

Funding for specific research collaboration activities including target identification, validation, and preclinical development. GSK deal included £44.5M upfront plus up to £118M per target in milestone payments.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Pricing details3 tiers
1Takeda partnership deal valued at up to $500 million in milestones plus royalties
ModelOtherBilling cadenceMulti-year contract
Notes

Upfront payment, near-term payments based on target confirmation and validation, preclinical/development/regulatory/commercial milestones, royalty payments on product sales

engitix.com
2Takeda IBD expansion deal valued at up to $300 million in milestones plus royalties
ModelOtherBilling cadenceMulti-year contract
Notes

Upfront payment, additional near-term payments based on target validation, preclinical/development/regulatory/commercial milestones, royalty payments on commercialized products

engitix.com
3GSK collaboration deal worth up to £44.5M upfront plus £118M per target in milestone payments plus royalties
ModelOtherBilling cadenceMulti-year contract
Notes

Upfront and near-term payments of £44.5M, milestone payments up to £118M per target, tiered low-single digit royalties on future product sales

globenewswire.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Engitix develops and applies a proprietary human extracellular matrix (ECM) drug discovery platform that uses tissue- and disease-specific human ECM scaffolds, the Engitomix bioinformatics platform, 3D-ECM bioassays, and a patient biosample archive to identify and validate novel therapeutic targets and biomarkers in fibrosis, inflammation, and solid tumours. The company offers its platform to pharmaceutical partners via licensing and research collaboration agreements and also advances its own internal pipeline of ECM-targeted therapeutic candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Takeda deal worth more than $500M including upfront, milestones, and royalties for advanced fibrotic liver diseases
+4 more records
Product overview1 text field

Engitix is a biopharmaceutical company built around its proprietary human extracellular matrix (ECM) drug discovery platform. The platform consists of tissue- and disease-specific human ECM scaffolds (the 3D ECM Bioassays), the Engitomix Bioinformatics Platform for multi-omics data integration and AI/ML-driven analytics, and an extensive bioarchive. This core technology drives both proprietary pipeline assets (EGTX004, EGTX003, EGTX006 targeting solid tumours, inflammation, and fibrosis) and partnered drug discovery programmes with Takeda (advanced liver diseases, IBD) and GSK (liver fibrosis regression).

Product and service1 record
1ECM Platform (Human Extracellular Matrix Platform)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-08
Description

Strategic research collaboration and option agreement to identify and validate novel therapeutic targets for liver fibrosis regression. Engitix will use its proprietary human ECM Platform and multi-omics datasets to identify high-confidence targets. GSK will pay £44.5M upfront and near-term payments, up to £118M per target in milestone payments, plus tiered low-single digit royalties. GSK holds option to license resulting assays, datasets, and targets and lead further R&D and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-12
Description

Expanded collaboration to include discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Deal worth up to approximately $300M including upfront, milestone, and royalty payments. Builds on existing liver disease collaboration.

3Dompé farmaceutici
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-19
Description

Multi-year, multi-programme strategic R&D collaboration combined with Series A co-investment. Dompé provides access to its Exscalate AI supercomputing structure-based drug design platform, facilities, and expertise. Deal includes equity investment and milestones. Engitix retains full control over assets and programmes. Dompé eligible for clinical and commercial milestones and royalties.

engitix.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-17
Description

Collaboration and licensing agreement to discover and develop novel therapeutics for advanced fibrotic liver diseases including NASH. Engitix receives upfront payment, near-term payments for target validation, and is eligible for more than $500M in preclinical, development, regulatory, and commercial milestones, plus royalties. Takeda receives exclusive rights to develop and commercialize clinical candidates.

5Morphic Therapeutic
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-12-10
Description

Research collaboration to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease (IBD), affecting approximately 30% of Crohn's Disease patients. Engitix applies its ECM platform to identify and characterize target expression, including integrin and non-integrin expression. Collaboration successfully established disease-specific human fibrostenotic ECM platform for target ID.

engitix.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing therapies for fibrotic diseases, including integrin-targeting candidates. Pliant's scientific advisor Scott Turner was former CSO there, indicating direct overlap in fibrosis biology and integrin-based therapeutic approaches overlapping with Engitix's ECM-derived integrin targets.

2Morphic Therapeutic
TypeDirect peer
Description

Biotech developing oral integrin therapies for fibrostenotic inflammatory bowel disease. Morphic is also a partner of Engitix for ECM-related target identification, representing direct overlap in integrin biology and fibrostenotic IBD as a therapeutic area.

TypeBroad incumbent
Description

Established late-stage biotech with fibrosis-focused pipeline including pamrevlumab. Operates broadly in fibrotic disease drug development with multiple programmes across organs, overlapping with Engitix's fibrosis focus but at a more advanced clinical stage.

TypeBroad incumbent
Description

Mid-cap biotech with historical fibrosis and inflammation programmes (e.g., ziritaxestat) and a cell therapy platform. Operates broadly in adjacent therapeutic areas to Engitix, including inflammation and fibrotic diseases.

TypeEmerging player
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning. Recursion's platform-based discovery approach parallels Engitix's Engitomix bioinformatics platform, though Recursion operates across many therapeutic areas beyond fibrosis.

TypeEmerging player
Description

AI-native drug discovery company using its Centaur platform for target identification and design. Dompè (an Engitix partner) leverages its own Exscalate platform, indicating a shared ecosystem of AI-augmented drug discovery comparable to Engitix's approach.

TypeEmerging player
Description

Computational drug discovery platform combining physics-based simulation with ML. Operates a platform-plus-pipeline model with pharma collaborations, comparable to Engitix's hybrid platform/partnership strategy, though broader in scope.

TypeEmerging player
Description

ML-driven drug discovery company combining high-throughput biology and patient-derived data. Insitro's approach of using patient-relevant data to discover targets parallels Engitix's patient-centric ECM platform, though Insitro operates across multiple therapeutic areas.

TypeRegional player
Description

UK-based clinical-stage biotech with fibrosis and oncology programmes. Operates in similar therapeutic areas to Engitix (fibrosis, cancer) but is regionally focused on UK and targets small molecule discovery rather than ECM biology.

TypeOthers
Description

Gene therapy company focused on liver diseases including metabolic disorders and Wilson disease. Eduardo Bravo (Engitix's Chairman) is also Chairman at Vivet, indicating an overlapping board-level connection and similar focus on liver-directed therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Engitix

Biopharmaceutical Drug Discoveryengitix.com

Engitix is a London-based biotechnology company that partners with pharmaceutical companies to discover and validate ECM-targeted therapeutics for fibrosis, inflammation, and solid tumours using its proprietary human extracellular matrix drug discovery platform and bioinformatics data assets.

What Engitix does

Engitix is a London-based biotechnology company founded in 2016 as a spin-out of University College London's Institute for Liver and Digestive Health, developing a proprietary human extracellular matrix (ECM) drug discovery platform for fibrosis, inflammation, and solid tumours. The platform combines tissue- and disease-specific human ECM scaffolds, a 3D phenotypic screening capability, and the Engitomix bioinformatics platform — built on one of the world's largest proprietary human ECM datasets integrating mass-spectrometry, RNA-sequencing, imaging, and clinical metadata with AI/ML-driven analytics. Engitix holds an exclusive license from UCLB to foundational ECM decellularization patents invented by co-founder Dr Giuseppe Mazza.

The company operates a B2B partnership model, monetizing its platform through multi-year, multi-programme collaborations with pharmaceutical and biotechnology companies. Partnerships with Takeda (up to $500M for advanced fibrotic liver diseases plus up to $300M for fibrostenotic IBD), GSK (£44.5M upfront plus up to £118M per target in milestones for liver fibrosis regression), Dompè farmaceutici (Exscalate AI integration plus equity), and Morphic Therapeutic (fibrostenotic IBD) generate upfront fees, near-term payments tied to target validation, preclinical/development/regulatory/commercial milestones, and royalties on commercialized products. Engitix retains full control over its assets in these collaborations.

In parallel, Engitix has built an internal proprietary pipeline of discovery-stage assets — EGTX003 (inflammation/fibrosis), EGTX004 (solid tumours and advanced fibrosis), and EGTX006 (advanced fibrosis) — financed through approximately $79M of disclosed venture funding, led by Netherton Investments (Mike Platt/BlueCrest Capital) with Dompè as co-lead of the 2022 Series A. Headcount has grown to approximately 60-80 staff across London headquarters (WestWorks, White City Place) and a Cambridge, MA US subsidiary, supported by ISO 27001 certification and an expanding leadership team drawn from J&J, Novartis, Roche, GSK, and other major pharma organizations.

Engitix firmographics

Firmographics
Name
Engitix
Legal name
ENGITIX LIMITED
Website
https://engitix.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Engitix is a London-based biotechnology company that partners with pharmaceutical companies to discover and validate ECM-targeted therapeutics for fibrosis, inflammation, and solid tumours using its proprietary human extracellular matrix drug discovery platform and bioinformatics data assets.
Ownership category
akta.pro rank

Engitix industry classification

Industry
Product category
Biopharmaceutical Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug discovery services
  • Extracellular matrix platform
  • Fibrosis therapeutics
  • Oncology drug discovery
  • Biopharmaceutical research

Where Engitix is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Engitix business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Partnership and Licensing Revenue: Engitix generates revenue through strategic partnerships with pharmaceutical companies. Partners pay upfront fees, near-term payments for target validation, and milestone payments tied to preclinical, development, regulatory, and commercial achievements. Royalties are received on sales of commercialized products.
  2. Platform Technology Access Fees: Partners receive access to ECM platform capabilities, facilities, and expertise in exchange for fees and milestone considerations. Dompé partnership included direct access to facilities, resources, and Exscalate AI drug discovery platform.
  3. Research Collaboration Payments: Funding for specific research collaboration activities including target identification, validation, and preclinical development. GSK deal included £44.5M upfront plus up to £118M per target in milestone payments.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractTakeda partnership deal valued at up to $500 million in milestones plus royalties
OtherMulti-year contractTakeda IBD expansion deal valued at up to $300 million in milestones plus royalties
OtherMulti-year contractGSK collaboration deal worth up to £44.5M upfront plus £118M per target in milestone payments plus royalties

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Engitix product offering

Product offering

Core offering

Engitix develops and applies a proprietary human extracellular matrix (ECM) drug discovery platform that uses tissue- and disease-specific human ECM scaffolds, the Engitomix bioinformatics platform, 3D-ECM bioassays, and a patient biosample archive to identify and validate novel therapeutic targets and biomarkers in fibrosis, inflammation, and solid tumours. The company offers its platform to pharmaceutical partners via licensing and research collaboration agreements and also advances its own internal pipeline of ECM-targeted therapeutic candidates.

Product overview

Engitix is a biopharmaceutical company built around its proprietary human extracellular matrix (ECM) drug discovery platform. The platform consists of tissue- and disease-specific human ECM scaffolds (the 3D ECM Bioassays), the Engitomix Bioinformatics Platform for multi-omics data integration and AI/ML-driven analytics, and an extensive bioarchive. This core technology drives both proprietary pipeline assets (EGTX004, EGTX003, EGTX006 targeting solid tumours, inflammation, and fibrosis) and partnered drug discovery programmes with Takeda (advanced liver diseases, IBD) and GSK (liver fibrosis regression).

Differentiator

Problem solved

Functional benefit

Products and services

  • ECM Platform (Human Extracellular Matrix Platform)

Quantifiable outcome

  • Takeda deal worth more than $500M including upfront, milestones, and royalties for advanced fibrotic liver diseases
  • +4 more outcomes

Companies that use Engitix

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Engitix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Engitix partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • GSKcoreStrategic or Co-development Partner · 8 June 2026Strategic research collaboration and option agreement to identify and validate novel therapeutic targets for liver fibrosis regression. Engitix will use its proprietary human ECM Platform and multi-omics datasets to identify high-confidence targets. GSK will pay £44.5M upfront and near-term payments, up to £118M per target in milestone payments, plus tiered low-single digit royalties. GSK holds option to license resulting assays, datasets, and targets and lead further R&D and commercialization.
  • Takeda Pharmaceuticals (IBD Expansion)coreStrategic or Co-development Partner · 12 April 2022Expanded collaboration to include discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Deal worth up to approximately $300M including upfront, milestone, and royalty payments. Builds on existing liver disease collaboration.
  • Dompé farmaceuticicoreStrategic or Co-development Partner · 19 January 2022Multi-year, multi-programme strategic R&D collaboration combined with Series A co-investment. Dompé provides access to its Exscalate AI supercomputing structure-based drug design platform, facilities, and expertise. Deal includes equity investment and milestones. Engitix retains full control over assets and programmes. Dompé eligible for clinical and commercial milestones and royalties.
  • Takeda PharmaceuticalscoreStrategic or Co-development Partner · 17 September 2020Collaboration and licensing agreement to discover and develop novel therapeutics for advanced fibrotic liver diseases including NASH. Engitix receives upfront payment, near-term payments for target validation, and is eligible for more than $500M in preclinical, development, regulatory, and commercial milestones, plus royalties. Takeda receives exclusive rights to develop and commercialize clinical candidates.
  • Morphic TherapeuticminorStrategic or Co-development Partner · 10 December 2019Research collaboration to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease (IBD), affecting approximately 30% of Crohn's Disease patients. Engitix applies its ECM platform to identify and characterize target expression, including integrin and non-integrin expression. Collaboration successfully established disease-specific human fibrostenotic ECM platform for target ID.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Engitix competitors and assessment

Company assessment

Direct peers

  • Pliant Therapeutics: Clinical-stage biotech developing therapies for fibrotic diseases, including integrin-targeting candidates. Pliant's scientific advisor Scott Turner was former CSO there, indicating direct overlap in fibrosis biology and integrin-based therapeutic approaches overlapping with Engitix's ECM-derived integrin targets.
  • Morphic Therapeutic: Biotech developing oral integrin therapies for fibrostenotic inflammatory bowel disease. Morphic is also a partner of Engitix for ECM-related target identification, representing direct overlap in integrin biology and fibrostenotic IBD as a therapeutic area.

Broad incumbents

  • FibroGen: Established late-stage biotech with fibrosis-focused pipeline including pamrevlumab. Operates broadly in fibrotic disease drug development with multiple programmes across organs, overlapping with Engitix's fibrosis focus but at a more advanced clinical stage.
  • Galapagos NV: Mid-cap biotech with historical fibrosis and inflammation programmes (e.g., ziritaxestat) and a cell therapy platform. Operates broadly in adjacent therapeutic areas to Engitix, including inflammation and fibrotic diseases.

Emerging players

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Recursion's platform-based discovery approach parallels Engitix's Engitomix bioinformatics platform, though Recursion operates across many therapeutic areas beyond fibrosis.
  • Exscientia: AI-native drug discovery company using its Centaur platform for target identification and design. Dompè (an Engitix partner) leverages its own Exscalate platform, indicating a shared ecosystem of AI-augmented drug discovery comparable to Engitix's approach.
  • Schrödinger, Inc. Computational drug discovery platform combining physics-based simulation with ML. Operates a platform-plus-pipeline model with pharma collaborations, comparable to Engitix's hybrid platform/partnership strategy, though broader in scope.
  • Insitro: ML-driven drug discovery company combining high-throughput biology and patient-derived data. Insitro's approach of using patient-relevant data to discover targets parallels Engitix's patient-centric ECM platform, though Insitro operates across multiple therapeutic areas.

Regional players

  • Redx Pharma: UK-based clinical-stage biotech with fibrosis and oncology programmes. Operates in similar therapeutic areas to Engitix (fibrosis, cancer) but is regionally focused on UK and targets small molecule discovery rather than ECM biology.

Others

  • Vivet Therapeutics: Gene therapy company focused on liver diseases including metabolic disorders and Wilson disease. Eduardo Bravo (Engitix's Chairman) is also Chairman at Vivet, indicating an overlapping board-level connection and similar focus on liver-directed therapeutics.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Engitix social profiles

Digital presence

Engitix compliance and trust

Trust signal

Compliance1 record

Engitix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Engitix leadership team

Management profile

Number of profiles

Profiles11 records

Engitix subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Engitix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Engitix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Engitix

What does Engitix do?

Engitix develops and applies a proprietary human extracellular matrix (ECM) drug discovery platform that uses tissue- and disease-specific human ECM scaffolds, the Engitomix bioinformatics platform, 3D-ECM bioassays, and a patient biosample archive to identify and validate novel therapeutic targets and biomarkers in fibrosis, inflammation, and solid tumours. The company offers its platform to pharmaceutical partners via licensing and research collaboration agreements and also advances its own internal pipeline of ECM-targeted therapeutic candidates.

Is Engitix a public or private company?

Engitix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Engitix founded?

Engitix was founded in 2016. It employs 51 to 100 people.

Where is Engitix based?

Engitix is headquartered in London, United Kingdom, in the Europe region.

How does Engitix make money?

Three revenue lines are on record. Partnership and Licensing Revenue is the primary driver. The others are platform Technology Access Fees and research Collaboration Payments.

Who are Engitix's main competitors?

Direct peers on record are Pliant Therapeutics and Morphic Therapeutic. Broad incumbents are FibroGen and Galapagos NV. Emerging players are Recursion Pharmaceuticals, Exscientia, Schrödinger, Inc. and Insitro. Redx Pharma is listed as a regional player. Vivet Therapeutics is listed as an others.

Does Engitix have an API?

No public API is recorded for Engitix.

What industry is Engitix in?

Engitix's product category is Biopharmaceutical Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPrimary Sclerosing Cholangitis Drugs In Development 2026: Pipeline Therapies, Ongoing Trials, And Companies Driving Innovation Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade PharmaPrimary sclerosing cholangitis (PSC) pipeline therapies are advancing, with Mirum's volixibat achieving a primary endpoint in its Phase IIb VISTAS trial and receiving FDA Breakthrough and Orphan Drug designations. Other candidates include norucholic acid, nebokitug, and elafibranor, with several companies planning Phase III trials or regulatory filings in 2026-2027.Pulse 2.0Engitix Appoints Former BioNTech Executive Ryan Richardson To Board Of DirectorsEngitix appointed Ryan Richardson as an independent non-executive director. He previously served as chief strategy officer at BioNTech, helping raise over $1 billion in equity capital. The company expects his experience to support its pipeline toward clinical development.GlobeNewswireEngitix appoints Ryan Richardson to Board of Directors as company advances towards clinical developmentEngitix appointed Ryan Richardson as Independent Non-Executive Director, citing his experience in biotechnology strategy and AI. He previously led BioNTech through its IPO and raised over $1 billion in equity. The appointment comes as Engitix advances its ECM-based drug discovery pipeline toward clinical development.BioPharm InternationalLonza, Engitix Ink ADC License Deal for ECM-Targeted Cancer, Fibrosis TherapiesLonza and Engitix announced a licensing agreement granting Engitix access to Lonza's SYNtecan E, GlycoConnect, and HydraSpace ADC technologies for ECM-targeted therapies. The deal includes upfront, milestone, and royalty payments, with Lonza manufacturing components and Engitix handling development and commercialization. Specific target, deal value, and timeline were not disclosed.The Pharma LetterEngitix appoints Sonia Quaratino as CMOEngitix appointed Dr Sonia Quaratino as executive vice president and chief medical officer. She brings over 35 years of experience in immunology, oncology, and clinical development, with interests in chronic inflammatory diseases and cancer. Her expertise aligns with Engitix's ECM-driven drug discovery mission.The future of tradingEngitix appoints Sonia Quaratino, MD, PhD as EVP Chief Medical Officer as its ECM pipeline moves toward clinical developmentEngitix appointed Sonia Quaratino, MD, PhD, as Executive Vice President Chief Medical Officer, effective immediately. She brings over 35 years of experience in immunology and oncology, and will lead clinical strategy as the company advances its ECM-targeting pipeline toward clinical trials.PharmafileLonza and Engitix partner to develop next-generation antibody-drug conjugatesLonza and Engitix signed a licensing agreement to develop antibody-drug conjugates, combining Engitix's ECM-based discovery platform with Lonza's conjugation and linker-payload technologies. Lonza will receive upfront, clinical, regulatory, and commercial milestone payments plus royalties, while Engitix handles R&D and commercialization.GenengnewsEngitix Licenses Lonza’s Technology to Advance ADC TherapiesLonza and Engitix signed a licensing agreement to advance antibody-drug conjugate (ADC) therapies for chronic diseases. Engitix will use Lonza's SYNtecan E linker-payload and GlycoConnect and HydraSpace technologies, with Lonza eligible for milestone payments and royalties. The collaboration aims to develop ECM-targeted therapeutics using Engitix's proprietary discovery platform.Longevity.TechnologyCan liver fibrosis be undone? Engitix, GSK aim to find outLondon-based biotech Engitix announced a strategic collaboration with GSK to identify biological mechanisms linked to liver fibrosis regression, shifting the focus from slowing organ scarring to understanding how scarred tissue may heal itself. Engitix will use its proprietary extracellular matrix platform to generate human tissue-based disease models and datasets to uncover recovery signals, while GSK can license the resulting assays, datasets and targets and lead further development and commercialization. The deal could be worth up to $60 million in upfront and near-term payments plus potential milestone payments of up to $159 million per target, plus royalties on future product sales.pharmaphorumGSK pursues $10.6bn takeover of cancer biotech NuvalentGSK agreed to buy Nuvalent for $10.6 billion, offering $124 per share, a 40% premium. The deal adds two late-stage lung cancer drugs, zidesamtinib and neladalkib, with FDA decisions due in September and November. GSK expects multi-blockbuster potential and a $5-7 billion annual sales peak.